Blocking CTLA-4 is capable of generating an immune response to cancer and self-tissue, and targeting the CD28/CTLA-4 pathway with antibodies has shown considerable promise in the treatment of cancer and autoimmune diseases. Here, CTLA4 is linked to autoimmune disease.